#PARPInhibitors Archives

ASCO-GU Interview | Dr. Yige Bao Shares Progress in PARPi Precision Treatment of Prostate Cancer and His Team’s Research on Neoadjuvant Therapy for UTUC

By Mourabit Halima 2024.03.07

Editor's Note: The annual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) was recently held in San Francisco, USA. Over its twenty-year history, the ASCO-GU Symposium has witnessed the…

ASCO-GU Interview | Dr. Pengfei Shen Interprets PROpel Study, Shares Genetic Testing to Guide Precise Treatment of Prostate Cancer

By Mourabit Halima 2024.03.04

Editor's Note: Following the breakthrough of the PROfound study, which marked the beginning of precision treatment for prostate cancer, the PROpel study has further extended the application of PARP inhibitors…

ASCO-GU Interview | Dr. Shun Zhang: The Value and Development of Genetic Testing in Precision Treatment of Prostate Cancer

By Mourabit Halima 2024.03.04

Editor's note: Precision treatment begins with testing. PARP inhibitors (PARPi) such as olaparib have become a precision treatment option for metastatic castration-resistant prostate cancer (mCRPC), offering therapeutic benefits to patients…

ASCO-GU Interview | Dr. Junlong Zhuang Interprets the BRCAAway Study and Real-World Genetic Testing in Advanced Prostate Cancer

By Mourabit Halima 2024.03.04

Editor's Note: In the field of metastatic castration-resistant prostate cancer (mCRPC), the PROfound study marked the beginning of the era of precision targeted therapy for prostate cancer, while the PROpel…